Bristol-Myers Squibb Company (BMY) 57.19 $BMY
Multi-Billion Dollar Cancer Treatment & Patient Care Industry Boosting Biotech Sector to New Highs
PR Newswire Europe - 2 hrs 39 mins ago
CORAL SPRINGS, Florida, September 8, 2016 /PRNewswire/ --
AGN: 239.91 (+1.49), MRK: 62.98 (+0.11), MYL: 40.75 (+0.44), BMY: 57.19 (+0.62)
Bristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27
BusinessWire - Wed Sep 07, 10:17AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016. During a conference call at 10:30 a.m. EDT on October 27, company executives will review financial information and will address inquiries from investors and analysts.
BMY: 57.19 (+0.62)
Bristol-Myers' Orencia Gains EU Approval for Expanded Use
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 9:59AM CDT
Bristol-Myers' (BMY) Orencia gains approval in the EU for label expansion.
GERN: 3.04 (-0.01), BMY: 57.19 (+0.62), CORT: 5.72 (+0.01), ANIK: 47.68 (-0.63)
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
BusinessWire - Wed Sep 07, 9:41AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch Global Health Care Conference on Wednesday, September 14, 2016, in London. John Elicker, senior vice president, Public Affairs and Investor Relations, will make a formal presentation about the company at 1 p.m. BST (8 a.m. EDT).
BMY: 57.19 (+0.62)
Watch for Shares of Bristol-Myers Squibb (BMY) to Approach Resistance at $57.74
Comtex SmarTrend(R) - Wed Sep 07, 9:19AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $56.74 today and has reached the first level of resistance at $57.35. Analysts will be watching for a cross of the next upside pivot targets of $57.74 and $58.75.
BMY: 57.19 (+0.62)
Bristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research
BusinessWire - Wed Sep 07, 5:59AM CDT
--Bristol-Myers Squibb will match money raised, dollar-for-dollar, up to $500,000
BMY: 57.19 (+0.62)
New Research Reports for September 6, 2016
Sheraz Mian - Zacks Investment Research - Tue Sep 06, 5:09PM CDT
New Research Reports for September 6, 2016
MU: 17.30 (+0.14), STT: 70.53 (-0.04), DAL: 39.07 (+0.17), ADI: 61.50 (-0.15), BMY: 57.19 (+0.62), MAC: 82.83 (-0.81)
Fitch: Global Pharma Perseveres on Cancer Treatments
BusinessWire - Tue Sep 06, 3:35PM CDT
Development of cancer therapies remains a focus for many global pharmaceutical companies despite three recent late-stage trial shortfalls, according to a new special report by Fitch Ratings.
BMY: 57.19 (+0.62)
Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
BusinessWire - Tue Sep 06, 11:14AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2016 Global Health Care Conference on Tuesday, September 13, 2016, in New York. Giovanni Caforio, M.D., chief executive officer will make formal remarks about the company and answer questions at 11:10 a.m. EDT.
BMY: 57.19 (+0.62), MS: 31.73 (+0.04)
European Commission Approves Bristol-Myers Squibb's ORENCIA(R) (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate
BusinessWire - Tue Sep 06, 5:59AM CDT
--This approval marks the first time that MRI assessment of structural and inflammatory measures of disease severity are cited in SmPC to support an RA indication
BMY: 57.19 (+0.62)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.98 (+0.11), MYL: 40.75 (+0.44), TEVA: 51.41 (+0.12), BMY: 57.19 (+0.62), NVS: 80.53 (+0.17)
Covered Call reports for Twitter, Incyte Corp., Chico's FAS Inc., SolarCity and Bristol-Myers Squibb include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Sep 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BMY, CHS, INCY, SCTY, and TWTR.
SCTY: 17.28 (-0.78), INCY: 82.14 (-0.31), BMY: 57.19 (+0.62), TWTR: 19.21 (-0.66), CHS: 12.57 (-0.03)
Biohaven Announces Series A Financing of Kleo Pharmaceuticals and Enters Into Clinical Development Master Services Agreement
Marketwire Canada - Thu Sep 01, 2:00AM CDT
Kleo Pharmaceuticals, Inc. Is Developing a New Class of Targeted Immunotherapies Utilizing Small Molecules to Fight Cancer and Infectious Disease
BMY: 57.19 (+0.62)
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights
BusinessWire - Wed Aug 31, 6:05PM CDT
Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference on Sunday, October 9, 2016, at 7:30 p.m. CEST (1:30 p.m. EDT) to discuss data presented at the European Society of Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. Company executives will provide an overview of data presented at the meeting, with a focus on the company's Immuno-Oncology portfolio, and address inquiries from investors and analysts.
BMY: 57.19 (+0.62)
Bristol-Myers Squibb Falls 1.32% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 30, 12:04PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $57.85 to a high of $58.97. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $58.36 on volume of 5.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 57.19 (+0.62)
Look for Shares of Bristol-Myers Squibb to Potentially Rebound after Yesterday's 1.32% Sell Off
Comtex SmarTrend(R) - Tue Aug 30, 12:02PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $57.85 to a high of $58.97. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $58.36 on volume of 5.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 57.19 (+0.62)
Watch for Shares of Bristol-Myers Squibb (BMY) to Approach Support at $58.11
Comtex SmarTrend(R) - Tue Aug 30, 9:13AM CDT
Shares of Bristol-Myers Squibb (NYSE:BMY) have bearishly opened below the pivot of $58.79 today and have reached the first support level of $58.43. Investors may be interested in a cross of the next downside pivot targets of $58.11 and $57.43.
BMY: 57.19 (+0.62)
Multi-Billion Dollar Cancer Treatment & Patient Care Industry Boosting Biotech Sector to New Highs
PR Newswire Europe - 2 hrs 39 mins ago
CORAL SPRINGS, Florida, September 8, 2016 /PRNewswire/ --
AGN: 239.91 (+1.49), MRK: 62.98 (+0.11), MYL: 40.75 (+0.44), BMY: 57.19 (+0.62)
Bristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27
BusinessWire - Wed Sep 07, 10:17AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016. During a conference call at 10:30 a.m. EDT on October 27, company executives will review financial information and will address inquiries from investors and analysts.
BMY: 57.19 (+0.62)
Bristol-Myers' Orencia Gains EU Approval for Expanded Use
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 9:59AM CDT
Bristol-Myers' (BMY) Orencia gains approval in the EU for label expansion.
GERN: 3.04 (-0.01), BMY: 57.19 (+0.62), CORT: 5.72 (+0.01), ANIK: 47.68 (-0.63)
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
BusinessWire - Wed Sep 07, 9:41AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch Global Health Care Conference on Wednesday, September 14, 2016, in London. John Elicker, senior vice president, Public Affairs and Investor Relations, will make a formal presentation about the company at 1 p.m. BST (8 a.m. EDT).
BMY: 57.19 (+0.62)
Watch for Shares of Bristol-Myers Squibb (BMY) to Approach Resistance at $57.74
Comtex SmarTrend(R) - Wed Sep 07, 9:19AM CDT
Bristol-Myers Squibb (NYSE:BMY) has opened bullishly above the pivot of $56.74 today and has reached the first level of resistance at $57.35. Analysts will be watching for a cross of the next upside pivot targets of $57.74 and $58.75.
BMY: 57.19 (+0.62)
Bristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research
BusinessWire - Wed Sep 07, 5:59AM CDT
--Bristol-Myers Squibb will match money raised, dollar-for-dollar, up to $500,000
BMY: 57.19 (+0.62)
New Research Reports for September 6, 2016
Sheraz Mian - Zacks Investment Research - Tue Sep 06, 5:09PM CDT
New Research Reports for September 6, 2016
MU: 17.30 (+0.14), STT: 70.53 (-0.04), DAL: 39.07 (+0.17), ADI: 61.50 (-0.15), BMY: 57.19 (+0.62), MAC: 82.83 (-0.81)
Fitch: Global Pharma Perseveres on Cancer Treatments
BusinessWire - Tue Sep 06, 3:35PM CDT
Development of cancer therapies remains a focus for many global pharmaceutical companies despite three recent late-stage trial shortfalls, according to a new special report by Fitch Ratings.
BMY: 57.19 (+0.62)
Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
BusinessWire - Tue Sep 06, 11:14AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2016 Global Health Care Conference on Tuesday, September 13, 2016, in New York. Giovanni Caforio, M.D., chief executive officer will make formal remarks about the company and answer questions at 11:10 a.m. EDT.
BMY: 57.19 (+0.62), MS: 31.73 (+0.04)
European Commission Approves Bristol-Myers Squibb's ORENCIA(R) (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate
BusinessWire - Tue Sep 06, 5:59AM CDT
--This approval marks the first time that MRI assessment of structural and inflammatory measures of disease severity are cited in SmPC to support an RA indication
BMY: 57.19 (+0.62)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.98 (+0.11), MYL: 40.75 (+0.44), TEVA: 51.41 (+0.12), BMY: 57.19 (+0.62), NVS: 80.53 (+0.17)
Covered Call reports for Twitter, Incyte Corp., Chico's FAS Inc., SolarCity and Bristol-Myers Squibb include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Sep 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BMY, CHS, INCY, SCTY, and TWTR.
SCTY: 17.28 (-0.78), INCY: 82.14 (-0.31), BMY: 57.19 (+0.62), TWTR: 19.21 (-0.66), CHS: 12.57 (-0.03)
Biohaven Announces Series A Financing of Kleo Pharmaceuticals and Enters Into Clinical Development Master Services Agreement
Marketwire Canada - Thu Sep 01, 2:00AM CDT
Kleo Pharmaceuticals, Inc. Is Developing a New Class of Targeted Immunotherapies Utilizing Small Molecules to Fight Cancer and Infectious Disease
BMY: 57.19 (+0.62)
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights
BusinessWire - Wed Aug 31, 6:05PM CDT
Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference on Sunday, October 9, 2016, at 7:30 p.m. CEST (1:30 p.m. EDT) to discuss data presented at the European Society of Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. Company executives will provide an overview of data presented at the meeting, with a focus on the company's Immuno-Oncology portfolio, and address inquiries from investors and analysts.
BMY: 57.19 (+0.62)
Bristol-Myers Squibb Falls 1.32% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 30, 12:04PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $57.85 to a high of $58.97. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $58.36 on volume of 5.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 57.19 (+0.62)
Look for Shares of Bristol-Myers Squibb to Potentially Rebound after Yesterday's 1.32% Sell Off
Comtex SmarTrend(R) - Tue Aug 30, 12:02PM CDT
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $57.85 to a high of $58.97. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $58.36 on volume of 5.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 57.19 (+0.62)
Watch for Shares of Bristol-Myers Squibb (BMY) to Approach Support at $58.11
Comtex SmarTrend(R) - Tue Aug 30, 9:13AM CDT
Shares of Bristol-Myers Squibb (NYSE:BMY) have bearishly opened below the pivot of $58.79 today and have reached the first support level of $58.43. Investors may be interested in a cross of the next downside pivot targets of $58.11 and $57.43.
BMY: 57.19 (+0.62)
